Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.06
-0.14 (-2.69%)
At close: Aug 14, 2026, 4:00 PM EDT
5.16
+0.10 (1.98%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
57
Market Cap
327.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 64.24M |
| Sutro Biopharma | 45.70M |
| Abeona Therapeutics | 25.52M |
| Opus Genetics | 9.86M |
| Vicore Pharma Holding AB | 370.61K |
| SAB Biotherapeutics | 114.70K |
IMRX News
- 9 days ago - Immuneering initiated with a Buy at H.C. Wainwright - TheFly
- 10 days ago - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 10 days ago - Immuneering Earnings release: Q2 2026 - Filings
- 10 days ago - Immuneering Quarterly report: Q2 2026 - Filings
- 25 days ago - Immuneering publishes preclinical data on atebimetinib in Cancer Research - TheFly
- 25 days ago - Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition - GlobeNewsWire
- 4 weeks ago - Immuneering Corporation Announces Grants of Inducement Awards - GlobeNewsWire
- 5 weeks ago - Immuneering initiated with an Overweight at Cantor Fitzgerald - TheFly